Abstract: An information processing system includes a storage, an interface device, and a computing circuit. The storage stores a database, in which spectrum data concerning light from a light source and a measurement condition data at a time of measurement of the light are associated with a plant status data concerning growth of a plant and/or a harvest data concerning a harvest of the plant. The interface device receives an input of a user measurement condition which is to be applied at a time of measurement of the plant by a user and which includes data concerning angles at the time of measurement and data concerning a plant status and/or a harvest to be predicted. The computing circuit determines at least two wavelengths contained in the light from the light source to be measured under the user measurement condition by referring to the database based on the user measurement condition.

Abstract: The spectroscopic measuring instrument includes: a spectrometer to make measurement of a reflection spectrum of an object relative to a light source and output measurement information representing a result of the measurement; a shadow projector including obstacle(s) to allow light from the light source to cast shadow(s) on an object surface; an imaging device to output image information representing an image of an imaging area including the object surface; a storage interface removably connectable to a computer readable medium; and a processing device. The processing device is connected to the spectrometer, the imaging device and the storage interface, and performs a measurement process of storing the measurement information from the spectrometer and the image information from the imaging device in the computer readable medium connected to the storage interface.

Abstract: The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.

Abstract: A method for producing a cancer cell aggregate having certain properties, screening a drug for preventing and/or treating cancer, and determining anoikis resistance in epithelial cancer cells. The method includes culturing cells using a cell culture substrate having a base material and a biocompatible polymer layer. The cell culture substrate has rough sections not covered with the biocompatible polymer layer on the surface of the cell culture substrate. Each of the rough sections has a shape of a spot with a diameter of 20-100 ?m, or a groove with a width of 3-30 ?m with an end part of the rough section being optionally connected to another rough section. A distance between two adjacent rough sections is at least 10 ?m or more, and the rough section has an uneven structure with a height ranging from 20 nm to 200 nm on the surface.

Abstract: A semiconductor optical device includes a substrate formed of silicon and having a first optical waveguide and a semiconductor element formed of a III-V compound semiconductor and having a second optical waveguide, the semiconductor element being bonded to an upper surface of the substrate. The first optical waveguide and the second optical waveguide form a directional coupler.

Abstract: [Problem] The objectives of the present invention are to provide a method for making an animal that has been stressed, in particular, chronically stressed, affect or develop a specific disease or symptom, and, through elucidating the process from loading stress to affection or onset of the disease or symptom, to provide a useful tool for research and development of preventing or treating methods of the disease or symptom. [Solution] The present invention relates to a method for producing a disease modeling non-human animal having cerebrovascular inflammation, the disease modeling non-human animal, a method for screening a drug using the disease modeling non-human animal, a method for determining the risk of a disease using the presence of cerebrovascular inflammation as an indicator, and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like.

Abstract: A polypeptide that comprises the amino acid sequence of SEQ ID NO: 1 and has a function of delivering a substance into cells, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 and has a function of degrading a nucleic acid molecule, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 and has a function of degrading a nucleic acid molecule and a function of intranuclearly migrating the same, polynucleotides encoding the respective polypeptides, and transformed cells containing the respective polynucleotides.

Abstract: A method for evaluating the progression of hepatic fibrosis in non-alcoholic steatohepatitis, said method comprising measuring the amount of a sugar chain having a structure represented by formula (I) and/or a precursor sugar chain of the biosynthesis of a sugar chain having a structure represented by formula (I) in a sample.

Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDP (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.

Abstract: A catalyst structure for synthesis gas production of a synthesis gas that contains carbon monoxide and hydrogen, the catalyst structure being provided with a carrier that has a porous structure, while being configured from a zeolite type compound; first catalyst particles that contain one or more iron group elements which are selected from the group consisting of nickel (Ni), iron (Fe) and cobalt (Co); and second catalyst particles that contain one or more platinum group elements which are selected from the group consisting of platinum (Pt), palladium (Pd), rhodium (Rh) and ruthenium (Ru). The catalyst structure for synthesis gas production has passages in communication with each other within the carrier. The first catalyst particles are present at least in the passages of the carrier; and the second catalyst particles are present at least either inside the carrier or on the outer surface of the carrier.

Abstract: A composition for activating cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. A composition for CTL activation for proliferation of cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. Moreover, a pharmaceutical composition for CTL activation or a food or a drink for CTL activation containing the composition for CTL activation is provided.

Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: , or a pharmaceutically acceptable salt thereof.

Abstract: It is an object of the present invention to provide a Japanese encephalitis preventive agent and a Japanese encephalitis vaccine agent, which are capable of imparting sufficient immunity to humans, even if these agents are used at a lower dose than the dose of a Japanese encephalitis vaccine for subcutaneous injection, or at a smaller number of administrations than the number of administrations of a Japanese encephalitis vaccine for subcutaneous injection. According to the present invention, provided is a Japanese encephalitis preventive agent, comprising a microneedle array having a sheet portion and a plurality of needle portions present on the upper surface of the sheet portion, wherein the aforementioned needle portions contain or carry an inactivated Japanese encephalitis virus.

Abstract: To provide a functional structural body that can realize a long life time by suppressing the decline in function of the functional substance and that can attempt to save resources without requiring a complicated replacement operation, and to provide a method for making the functional structural body. The functional structural body (1) includes a skeletal body (10) of a porous structure composed of a zeolite-type compound, and at least one functional substance (20) present in the skeletal body (10), the skeletal body (10) has channels (11) connecting with each other, and the functional substance is present at least in the channels (11) of the skeletal body (10).

Abstract: A laminate which allows to obtain an organic thin-film solar cell having excellent output characteristics and transparency is provided. The laminate as above has a titanium oxide layer that is disposed on the member serving as a light-transmissive electrode layer and serves as an electron transport layer. The titanium oxide layer has a thickness of not less than 1.0 nm and not more than 200.0 nm. The titanium oxide layer contains indium oxide and metallic indium, InOx/Ti is not less than 0.50 and not more than 20.00 in atomic ratio, and InM/Ti is less than 0.100 in atomic ratio, where an elemental titanium content is represented by Ti, an indium oxide content is represented by InOx, and a metallic indium content is represented by InM.

Abstract: Disclosed is oxide-containing copper fine particles including Cu64O and optionally Cu2O and coated with a carboxylic acid, wherein a mass ratio of Cu64O to a total mass of Cu, Cu64O and Cu2O is 0.5 to 2.0% by mass.

Abstract: A treatment device that shortens the time period until healing is determined even when a bone defect or a root apex lesion is generated in an apical area. The treatment device includes a file holder, a high-frequency signal generating circuit, and a control circuit. The file holder holds a file to be located in the site to be treated. The high-frequency signal generating circuit passes a high frequency current through the file. The control circuit controls a frequency of the high frequency current to be passed through the file from the high-frequency signal generating circuit. The control circuit controls the frequency of the high frequency current to be passed through the file within a range of 1.001 MHz to 11.700 MHz.

Abstract: The present invention makes it possible to provide a radiation therapy system capable of not only inhibiting treatment time from increasing more effectively than before but also reducing the loads of fluoroscopic radiation photographing apparatuses.

Abstract: A functional structural body that can realize a prolonged life time by suppressing the decrease in function and that can fulfill resource saving without requiring a complicated replacement operation is provided. A functional structural body includes a skeletal body of a porous structure composed of a zeolite-type compound; and at least one solid acid present in the skeletal body, the skeletal body has channels connecting with each other, and the solid acid is present at least in the channels of the skeletal body.

Abstract: Disclosed is a method for producing a mono-cross-coupled aromatic compound (3-1) having one less leaving group than an aromatic compound (1) having at least two leaving groups, the method comprising: preparing the aromatic compound (1) having at least two leaving groups; preparing a compound (2) capable of undergoing a cross-coupling reaction selected from an aromatic boronic acid (2-1), an aromatic amino compound (2-2), a diboronic acid ester (2-3), an aromatic compound (2-4) having a hydroxyl group and an aromatic compound (2-5) having a thiol group; and performing a cross-coupling reaction of the aromatic compound (1) having at least two leaving groups with the compound (2) in the presence of a palladium catalyst and a base, in the absence of a solvent.